{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:23:51Z","timestamp":1761513831042,"version":"3.41.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,20]],"date-time":"2016-06-20T00:00:00Z","timestamp":1466380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sunovion Pharmaceuticals Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["epilepsybehavior.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.yebeh.2016.05.010","type":"journal-article","created":{"date-parts":[[2016,6,15]],"date-time":"2016-06-15T14:44:56Z","timestamp":1466001896000},"page":"63-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users: A Phase I randomized controlled trial"],"prefix":"10.1016","volume":"61","author":[{"given":"Naama","family":"Levy-Cooperman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerri A.","family":"Schoedel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijan","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Blum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.yebeh.2016.05.010_bb0005","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1177\/0091270005279364","article-title":"Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects","volume":"45","author":"Almeida","year":"2005","journal-title":"J Clin Pharmacol"},{"issue":"Suppl. 6","key":"10.1016\/j.yebeh.2016.05.010_bb0010","article-title":"Inhibitory effects of eslicarbazepine acetate and its metabolites against neuronal voltage-gated sodium channels","volume":"52","author":"Hebeisen","year":"2011","journal-title":"Epilepsia"},{"issue":"2\u20133","key":"10.1016\/j.yebeh.2016.05.010_bb0015","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","article-title":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","volume":"89","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Res"},{"issue":"Suppl. 2","key":"10.1016\/j.yebeh.2016.05.010_bb0020","first-page":"209","article-title":"Efficacy of eslicarbazepine acetate in patients with refractory partial onset seizures: a pooled analysis of three phase III controlled studies","volume":"14","author":"Biton","year":"2014","journal-title":"Epilepsy Curr"},{"issue":"3","key":"10.1016\/j.yebeh.2016.05.010_bb0025","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.05.010_bb0030","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12883-015-0305-5","article-title":"Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study","volume":"15","author":"Jacobson","year":"2015","journal-title":"BMC Neurol"},{"issue":"Suppl. 1","key":"10.1016\/j.yebeh.2016.05.010_bb0035","first-page":"209","article-title":"Eslicarbazepine acetate as adjunctive treatment for refractory partial-onset seizures: pooled analysis of safety data from three phase III controlled trials","volume":"14","author":"Rogin","year":"2014","journal-title":"Epilepsy Curr"},{"issue":"2","key":"10.1016\/j.yebeh.2016.05.010_bb0040","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/epi.12894","article-title":"Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial","volume":"56","author":"Sperling","year":"2015","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.yebeh.2016.05.010_bb0045","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/epi.12934","article-title":"Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America","volume":"56","author":"Sperling","year":"2015","journal-title":"Epilepsia"},{"author":"Food and Drug Administration","key":"10.1016\/j.yebeh.2016.05.010_bb0050"},{"issue":"4","key":"10.1016\/j.yebeh.2016.05.010_bb0055","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/clpt.1994.55","article-title":"Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans","volume":"55","author":"Busto","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.yebeh.2016.05.010_bb0060","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3109\/10826088809039211","article-title":"Comparative study of the abuse liability of alprazolam, lorazepam, diazepam, methaqualone, and placebo","volume":"23","author":"Orzack","year":"1988","journal-title":"Int J Addict"},{"issue":"Suppl. 3","key":"10.1016\/j.yebeh.2016.05.010_bb0065","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0376-8716(03)00097-8","article-title":"Guidelines and methodological reviews concerning drug abuse liability assessment","volume":"70","author":"Balster","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"Suppl. 3","key":"10.1016\/j.yebeh.2016.05.010_bb0070","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0376-8716(03)00098-X","article-title":"Principles of initial experimental drug abuse liability assessment in humans","volume":"70","author":"Griffiths","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"Suppl. 1","key":"10.1016\/j.yebeh.2016.05.010_bb0075","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.drugalcdep.2006.01.015","article-title":"Research design strategies to evaluate the impact of formulations on abuse liability","volume":"83","author":"McColl","year":"2006","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.yebeh.2016.05.010_bb0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/clpt.2010.67","article-title":"Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users","volume":"88","author":"Schoedel","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.yebeh.2016.05.010_bb0085","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cpt1971122part1245","article-title":"Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man","volume":"12","author":"Martin","year":"1971","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.yebeh.2016.05.010_bb0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00008877-199302000-00001","article-title":"Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans","volume":"4","author":"Griffiths","year":"1993","journal-title":"Behav Pharmacol"},{"issue":"4","key":"10.1016\/j.yebeh.2016.05.010_bb0095","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.yebeh.2010.04.022","article-title":"Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers","volume":"18","author":"Milovan","year":"2010","journal-title":"Epilepsy Behav"},{"issue":"2","key":"10.1016\/j.yebeh.2016.05.010_bb0100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/13854049108403297","article-title":"The Hopkins verbal learning test: development of a new memory test with six equivalent forms","volume":"5","author":"Brandt","year":"1991","journal-title":"Clin Neuropsychol"},{"author":"Brandt","key":"10.1016\/j.yebeh.2016.05.010_bb0105"},{"key":"10.1016\/j.yebeh.2016.05.010_bb0110","series-title":"CPDD 74th annual meeting, Palm Springs, CA","first-page":"156","article-title":"Sensitivity and performance of derived parameters from human abuse potential studies","author":"Shram","year":"2012"},{"author":"Aptiom\u00ae (Eslicarbazepine Acetate)","key":"10.1016\/j.yebeh.2016.05.010_bb0115"},{"author":"Food and Drug Administration","key":"10.1016\/j.yebeh.2016.05.010_bb0120"},{"key":"10.1016\/j.yebeh.2016.05.010_bb0125","series-title":"Eight factors determinative of control and findings pursuant to 21 U.S.C. 812(b)","first-page":"1","article-title":"Schedules of controlled substances: placement of ezogabine into schedule V background, data, and analysis","author":"U.S. Department of Justice Drug Enforcement Administration","year":"2011"},{"author":"Vimpat\u00ae (lacosamide)","key":"10.1016\/j.yebeh.2016.05.010_bb0130"},{"author":"Food and Drug administration","key":"10.1016\/j.yebeh.2016.05.010_bb0135"},{"issue":"6","key":"10.1016\/j.yebeh.2016.05.010_bb0140","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0026-895X(25)08760-7","article-title":"Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin","volume":"47","author":"Granger","year":"1995","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.yebeh.2016.05.010_bb0145","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pbb.2008.01.001","article-title":"Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond","volume":"90","author":"Licata","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"issue":"1\u20132","key":"10.1016\/j.yebeh.2016.05.010_bb0150","first-page":"15","article-title":"The role of human drug self-administration procedures in the development of medications","volume":"96","author":"Comer","year":"2008","journal-title":"Drug Alcohol Depend"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016300919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016300919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T21:48:01Z","timestamp":1748987281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505016300919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":30,"alternative-id":["S1525505016300919"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2016.05.010","relation":{},"ISSN":["1525-5050"],"issn-type":[{"type":"print","value":"1525-5050"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users: A Phase I randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2016.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}